Free Biopharma Daily Stock Updates - 04/12/21

$XBI $127 -2%

$KNSA -9% Ph 2 data in severe covid-19 patients. source

$IMCR -6% ph 3 data presented at AACR. source

$VBIV 0% Ph 1b/2a data. source

$ALPN -9% Presented clinical data at AACR. source

$AVXL -9% DSMB recommends study continuations. source

$FGEN +8%Pamrevlumab receives Fast Track designation for DMD. source

$ONCY -18% Ph 1 data presented at AACR. source

$ZNTL +8% Clinical collab with $GSK. source

$MYOV -5% Ph 3 initiated w/ $PFE. source

$ORIC -9% Presented 4 preclin posters at AACR. source

$CRDF -3% Ph 1b/2 data. source

$GLSI -27% Ph 2b 5yr data at AACR. source

$PIRS -15% Presented ph 1 data at AACR. source

$ZNTL +8% Presented ph 1 data for ZN-c3 at AACR. source

$GLYC -11% Presented ph 1b data of GMI-1359 at AACR. source

$RCUS -3% Presented updated ph 1 data at AACR. source

$BPMC -2% Systemic Mastocytosis trials present outcomes data. source

$CMPI -21% Vidutolimod demonstrates improved response in melanoma trial. source

$ONCT -18% presented updates on cirmtuzumab trial. source

$RUBY -7% First patient dosed in Phase 1 RTX-321 clinical trial. source

$AGEN -3% Presented new data on AGEN 1181 Phase 2 trial and expanded indications. source

$BCYC -5% Presents posters on current and new assets at AACR 2021. source

$CDAK -6% exoIL-12 produces prolonged immune activation in Phase 1 trial. source

$SPPI -4% Cohort 5 of ZENITH20 trial reports preliminary data. source

$CRDF -3% New gene signature data of onvansertib in Phase 2 trial reported. source

$CLVS -2% Announced Phase 1b data and plans to enroll in Phase 3 study soon. source